Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03336619
Other study ID # RM08-3004
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date January 17, 2018
Est. completion date April 17, 2019

Study information

Verified date April 2022
Source Romark Laboratories L.C.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Trial to evaluate efficacy and safety of nitazoxanide (NTZ) in the treatment of uncomplicated influenza.


Description:

A multicenter, randomized, double-blind, placebo controlled trial to evaluate efficacy and safety of nitazoxanide (NTZ) in the treatment of uncomplicated influenza.


Recruitment information / eligibility

Status Completed
Enrollment 1030
Est. completion date April 17, 2019
Est. primary completion date April 17, 2019
Accepts healthy volunteers No
Gender All
Age group 12 Years and older
Eligibility Inclusion Criteria: 1. Male and female subjects at least 12 years of age 2. Presence of clinical signs and/or symptoms consistent with an acute illness compatible with influenza infection (each of the following is required): 1. oral temperature =99.4°F or =37.4°C (obtained in office or self- measured within 12 hours prior to screening - if self-measured, subjects must also have taken an antipyretic within 4 hours prior to screening), AND 2. at least one of the following respiratory symptoms (cough, sore throat, nasal obstruction), AND 3. one of the following constitutional symptoms (fatigue, headache, myalgia, feverishness). 3. Confirmation of influenza A or B infection in the local community by one of the following means: 1. the institution's local laboratory, 2. the local public health system, 3. the national public health system, OR 4. a laboratory of a recognized national or multinational influenza surveillance scheme. 4. Onset of illness no more than 40 hours before enrollment in the trial. Note: Time of onset of illness is defined as either the earlier of: 1. the time when the temperature was first measured as elevated, OR 2. the time when the subject experienced the presence of at least one respiratory symptom AND the presence of at least one constitutional symptom. 5. Willing and able to provide written informed consent (including assent by legal guardian if under 18 years of age) and comply with the requirements of the protocol, including completion of the patient diary. Exclusion Criteria: 1. Severity of illness requiring or anticipated to require in-hospital care. 2. Moderate or severe persistent asthma. 3. Cystic fibrosis in children. 4. Stage III or IV (severe or very severe) chronic obstructive pulmonary disease (COPD). 5. Class III or IV congestive heart failure (at least marked limitation of physical activity in which minimal ordinary activity results in fatigue, palpitation, dyspnea, or angina pain) 6. Arrhythmia 7. Immunosuppressive disorders or who are receiving immunosuppressive therapy (e.g., for organ or bone marrow transplants) 8. Untreated HIV infection or treated HIV infection with a CD4 count below 350 cells/mm3 in the last 6 months 9. Persons with sickle cell anemia or other hemoglobinopathies 10. Poorly controlled insulin-dependent diabetes mellitus (HBA1C > 8%) 11. Residents of any age of nursing homes or other long-term care institutions 12. Concurrent infection at the screening examination that requires systemic antimicrobial therapy. 13. Females of childbearing potential who are either pregnant, breast-feeding or are sexually active without the use of birth control. Female subjects of child-bearing potential that are sexually active must have a negative baseline pregnancy test and must agree to continue an acceptable method of birth control for the duration of the study and for 1 month post- treatment. A double barrier method, oral birth control pills administered for at least 2 monthly cycles prior to study drug administration, an IUD, or medroxyprogesterone acetate administered intramuscularly for a minimum of one month prior to study drug administration are acceptable methods of birth control for inclusion into the study. Female subjects are considered of childbearing potential unless they are postmenopausal (absence of menstrual bleeding for 1 year - or 6 months if laboratory confirmation of hormonal status), or have had a hysterectomy, bilateral tubular ligation or bilateral oophorectomy. 14. Receipt of any dose of NTZ, oseltamivir, zanamivir, peramivir, laninamivir, baloxavir, amantadine or rimantadine within 3 days prior to screening. 15. Prior treatment with any investigational drug therapy within 30 days prior to screening. 16. Subjects with active respiratory allergies or subjects expected to require anti-allergy medications during the study period for respiratory allergies. 17. Known sensitivity to NTZ or any of the excipients comprising the NTZ tablets. 18. Subjects unable to take oral medications. 19. Presence of any pre-existing illness that, in the opinion of the Investigator, would place the subject at an unreasonably increased risk through participation in this study. 20. Subjects who, in the judgment of the Investigator, will be unlikely to comply with the requirements of this protocol.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Nitazoxanide
Nitazoxanide 600 mg administered orally twice daily for five days
Placebo
Placebo administered orally twice daily for five days

Locations

Country Name City State
Australia Vanguard Study Site Morayfield Queensland
Australia Vanguard Study Site Sherwood Queensland
Australia Vanguard Study Site Victoria Point Queensland
Puerto Rico Vanguard Study Site Ponce
United States Vanguard Study Site Alabaster Alabama
United States Vanguard Study Site Anaheim California
United States Vanguard Study Site Austin Texas
United States Vanguard Study Site Birmingham Alabama
United States Vanguard Study Site Birmingham Alabama
United States Vanguard Study Site Brooklyn New York
United States Vanguard Study Site Carrollton Texas
United States Vanguard Study Site Cincinnati Ohio
United States Vanguard Study Site Columbus Ohio
United States Vanguard Study Site Dallas Texas
United States Vanguard Study Site Dallas Texas
United States Vanguard Study Site Dayton Ohio
United States Vanguard Study Site Fort Worth Texas
United States Vanguard Study Site Goodyear Arizona
United States Vanguard Study Site Hoover Alabama
United States Vanguard Study Site Hot Springs Arkansas
United States Vanguard Study Site Houston Texas
United States Vanguard Study Site Jackson Tennessee
United States Vanguard Study Site Lauderdale Lakes Florida
United States Vanguard Study Site Medford Oregon
United States Vanguard Study Site Missoula Montana
United States Vanguard Study Site New Orleans Louisiana
United States Vanguard Study Site Orlando Florida
United States Vanguard Study Site Pelham Alabama
United States Vanguard Study Site Pharr Texas
United States Vanguard Study Site Plano Texas
United States Vanguard Study Site Plano Texas
United States Vanguard Study Site Rapid City South Dakota
United States Vanguard Study Site Saint George Utah
United States Vanguard Study Site Saint Louis Missouri
United States Vanguard Study Site Smyrna Tennessee
United States Vanguard Study Site Tolleson Arizona
United States Vanguard Study Site Valparaiso Indiana
United States Vanguard Study Site Westminster California

Sponsors (1)

Lead Sponsor Collaborator
Romark Laboratories L.C.

Countries where clinical trial is conducted

United States,  Australia,  Puerto Rico, 

Outcome

Type Measure Description Time frame Safety issue
Other Time to Return to Usual Health Subjects completed the FLU-PRO questionnaire including global assessment questions daily in the evening. The time from first dose to ability to return to usual health is the time in hours from the first dose of study medication to the first time when the subject answered "Have you returned to your usual health?" with "yes" for two consecutive daily diary periods without the use of symptom relief medication. 21 days
Other Proportion of Diaries Misclassified by Novel Response Definition The proportion of patient diaries misclassified by the response definition used for the primary efficacy analysis compared to patient reported usual health. A diary was considered "misclassified" if the response definition predicted "responded" and the patient reported not being at usual health or if the response definition predicted "not responded" and the patient reported being at usual health. 21 days
Primary Time From First Dose to Symptom Response Subjects used the FLU-PRO questionnaire once daily in the evening to score the severity of 32 FLU-PRO symptoms. Symptom response was deemed achieved when the rating for each of the 32 FLU-PRO symptoms was = its assigned threshold for 2 consecutive daily diary periods without use of symptom relief medication. The symptom response thresholds were developed by applying an algorithm to blinded symptoms data to select the set of 32 symptom thresholds most closely associated with patient-reported usual health. Up to 21 days
Secondary Time From First Dose to Ability to Perform All Normal Activities Subjects completed a diary including rating ability to perform normal activities on a scale from 0 (able to perform no normal activities) to 10 (able to perform all normal activities) daily in the evening. The time from first dose to ability to perform all normal activities is the time in hours between the first dose of study medication and that time when the subject first reported a score of "10" (able to perform all normal activities) for two consecutive daily diary periods without use of symptom relief medication. Up to 21 days
Secondary Number of Subjects Experiencing One or More Complications of Influenza Complications of influenza infection included pneumonia, otitis media, bronchitis, sinusitis, worsening of pre-existing health conditions, systemic antibiotic use for infections secondary to influenza infection, hospitalization due to influenza or complications of influenza and death. Up to 21 days
Secondary Time to Symptom Response Excluding the FLU-PRO Gastrointestinal and Eye Domains Subjects used the FLU-PRO questionnaire once daily in the evening to score the severity of 32 FLU-PRO symptoms. Symptom response was deemed achieved when the rating for each of the 25 FLU-PRO symptoms (excluding gastrointestinal and eye symptoms) was = its assigned threshold for 2 consecutive daily diary periods without use of symptom relief medication. The symptom response thresholds were developed by applying an algorithm to blinded symptoms data to select the set of 25 symptom thresholds most closely associated with patient-reported usual health. Up to 21 days
See also
  Status Clinical Trial Phase
Completed NCT05523089 - The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults Phase 2
Completed NCT05009251 - Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake N/A
Completed NCT03282240 - Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US Phase 3
Completed NCT00968526 - Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT00971425 - Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1) Phase 3
Completed NCT00968539 - Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT05525494 - Patient Portal Flu Vaccine Reminders (5) N/A
Completed NCT04074928 - Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects Phase 3
Completed NCT04695717 - This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam Phase 3
Completed NCT05012163 - Lottery Incentive Nudges to Increase Influenza Vaccinations N/A
Completed NCT03888989 - Response to Influenza Vaccine During Pregnancy Phase 1
Completed NCT04109222 - Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively Phase 4
Completed NCT02587221 - Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age Phase 3
Completed NCT03453801 - The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection Phase 1
Completed NCT01440387 - A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older Phase 3
Terminated NCT01195779 - Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children Phase 2
Completed NCT03321968 - Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults Phase 3
Completed NCT00972517 - Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children Phase 3
Completed NCT04570904 - Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
Recruiting NCT03331991 - Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel N/A